Exopeptidase combination enhances the degradation of isotopically labelled gluten immunogenic peptides in humans
AMYNOPEP achieved complete degradation of the 33-mer into single amino acids and dipeptides <i>in vitro</i> and significantly improved 33-mer degradation kinetics in healthy volunteers, as measured by labelled amino acid detection, warranting further investigation into the potential therapeutic benefits of exopeptidase combinations for patients with gluten-related health disorders including celiac disease.
Authors
- Mladen V. Tzvetkov (ORCID: https://orcid.org/0000-0003-1670-5534)
- Werner Weitschies (ORCID: https://orcid.org/0000-0003-3492-7747)
- Fabian Winter (ORCID: https://orcid.org/0000-0002-4195-4463)
- Sarah Römer
- Sulayman Mourabit (ORCID: https://orcid.org/0009-0002-5700-2245)
- Stefan Engeli (ORCID: https://orcid.org/0000-0002-3087-971X)
- Erin R. Bonner (ORCID: https://orcid.org/0000-0002-1299-6330)
- Julian Tschollar
- Werner Tschollar
Institutions
- Universitätsmedizin Greifswald (DE)
- Universität Greifswald (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3389/fimmu.2024.1425982
- Citations
- 3
- Primary Topic
- Celiac Disease Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.39